The α-recist (recist 1.1 combined with alpha fetoprotein): a novel tool for identifying tumor response of conversion-radiother

HIGHLIGHTS

• who: Ying Xu from the Military Command, China University of Kong have published the research work: The u03b1-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiother, in the Journal: (JOURNAL)
• what: The primary endpoint of this study was RFS, which was calculated from the date of radical hepatectomy to recurrence or the last follow-up. The authors investigated different modified versions of tumor response criteria by combining AFPD, AFPBL with RECIST 1.1, mRECIST. The authors think it may be explained by the following reasons . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.